BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fecteau H, Vogel KJ, Hanson K, Morrill-Cornelius S. The evolution of cancer risk assessment in the era of next generation sequencing. J Genet Couns 2014;23:633-9. [PMID: 24756768 DOI: 10.1007/s10897-014-9714-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Chadwell SE, He H, Knapke S, Lewis J, Sisson R, Hopper J. Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing. J Genet Counsel 2018;27:1210-9. [DOI: 10.1007/s10897-018-0241-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Kamps R, Brandão RD, Bosch BJ, Paulussen AD, Xanthoulea S, Blok MJ, Romano A. Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int J Mol Sci 2017;18:E308. [PMID: 28146134 DOI: 10.3390/ijms18020308] [Cited by in Crossref: 193] [Cited by in F6Publishing: 161] [Article Influence: 38.6] [Reference Citation Analysis]
3 Esteban I, Lopez-Fernandez A, Balmaña J. A narrative overview of the patients' outcomes after multigene cancer panel testing, and a thorough evaluation of its implications for genetic counselling. Eur J Med Genet 2019;62:342-9. [PMID: 30476626 DOI: 10.1016/j.ejmg.2018.11.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Price KS, Svenson A, King E, Ready K, Lazarin GA. Inherited Cancer in the Age of Next-Generation Sequencing. Biol Res Nurs 2018;20:192-204. [PMID: 29325452 DOI: 10.1177/1099800417750746] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Angione K, Gibbons M, Demarest S. An Objective Method for Evaluating Next-Generation Sequencing Panels. J Child Neurol 2019;34:139-43. [PMID: 30569809 DOI: 10.1177/0883073818815036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Long JM, Powers JM, Katona BW. Evaluation of Classic, Attenuated, and Oligopolyposis of the Colon. Gastrointest Endosc Clin N Am 2022;32:95-112. [PMID: 34798989 DOI: 10.1016/j.giec.2021.08.003] [Reference Citation Analysis]
7 Courtney E, Li ST, Shaw T, Chen Y, Allen JC Jr, Ngeow J. Predictors of next-generation sequencing panel selection using a shared decision-making approach. NPJ Genom Med 2018;3:11. [PMID: 29736259 DOI: 10.1038/s41525-018-0050-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 White VB, Walsh KK, Foss KS, Amacker-north L, Lenarcic S, Mcneely L, White RL. Genetic Testing for Hereditary Breast Cancer: The Decision to Decline. The American Surgeon 2018;84:154-60. [DOI: 10.1177/000313481808400139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Fahrioğlu U. Problems of Unknown Significance: Counseling in the Era of Next Generation Sequencing. Balkan J Med Genet 2018;21:73-6. [PMID: 30425914 DOI: 10.2478/bjmg-2018-0003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Fecteau H, Pal T. Clinical Considerations in the Conduct of Cancer Next-Generation Sequencing Testing and Genetic Counseling. In: Wu W, Choudhry H, editors. Next Generation Sequencing in Cancer Research, Volume 2. Cham: Springer International Publishing; 2015. pp. 81-101. [DOI: 10.1007/978-3-319-15811-2_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH; BRCA TtoT Community of Practice. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. J Med Genet 2018;55:571-7. [PMID: 30042185 DOI: 10.1136/jmedgenet-2018-105472] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
12 Patenaude AF, Schneider KA. Issues Arising in Psychological Consultations to Help Parents Talk to Minor and Young Adult Children about their Cancer Genetic Test Result: a Guide to Providers. J Genet Counsel 2017;26:251-60. [DOI: 10.1007/s10897-016-0010-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
13 Gomy I, Diz Mdel P. Hereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era. Genet Mol Biol 2016;39:184-8. [PMID: 27192130 DOI: 10.1590/1678-4685-GMB-2014-0346] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 O'Leary E, Iacoboni D, Holle J, Michalski ST, Esplin ED, Yang S, Ouyang K. Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer Risk. Ann Surg Oncol 2017;24:3060-6. [PMID: 28766213 DOI: 10.1245/s10434-017-5963-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
15 Liu X, Takata S, Ashikawa K, Aoi T, Kosugi S, Terao C, Parrish NF, Matsuda K, Nakagawa H, Kamatani Y, Kubo M, Momozawa Y. Prevalence and Spectrum of Pathogenic Germline Variants in Japanese Patients With Early-Onset Colorectal, Breast, and Prostate Cancer. JCO Precis Oncol 2020;4:183-91. [PMID: 35050733 DOI: 10.1200/PO.19.00224] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Tafe LJ. Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes. The Journal of Molecular Diagnostics 2015;17:472-82. [DOI: 10.1016/j.jmoldx.2015.06.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
17 Lincoln SE, Kobayashi Y, Anderson MJ, Yang S, Desmond AJ, Mills MA, Nilsen GB, Jacobs KB, Monzon FA, Kurian AW, Ford JM, Ellisen LW. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. J Mol Diagn 2015;17:533-44. [PMID: 26207792 DOI: 10.1016/j.jmoldx.2015.04.009] [Cited by in Crossref: 115] [Cited by in F6Publishing: 104] [Article Influence: 16.4] [Reference Citation Analysis]
18 Grady MC, Kolla KA, Peshkin BN. Multigene Cancer Panels: Implications for Pre- and Post-test Genetic Counseling. Curr Genet Med Rep 2019;7:169-79. [DOI: 10.1007/s40142-019-00173-8] [Reference Citation Analysis]
19 Profato JL, Arun BK. Genetic risk assessment for breast and gynecological malignancies. Curr Opin Obstet Gynecol 2015;27:1-5. [PMID: 25502427 DOI: 10.1097/GCO.0000000000000142] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Bradbury AR, Patrick-Miller L, Long J, Powers J, Stopfer J, Forman A, Rybak C, Mattie K, Brandt A, Chambers R, Chung WK, Churpek J, Daly MB, Digiovanni L, Farengo-Clark D, Fetzer D, Ganschow P, Grana G, Gulden C, Hall M, Kohler L, Maxwell K, Merrill S, Montgomery S, Mueller R, Nielsen S, Olopade O, Rainey K, Seelaus C, Nathanson KL, Domchek SM. Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med 2015;17:485-92. [PMID: 25297947 DOI: 10.1038/gim.2014.134] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
21 Keller H, Wusik K, He H, Yager G, Atzinger C. Further validation of the Genetic Counseling Self‐Efficacy Scale (GCSES): Its relationship with personality characteristics. Jrnl of Gene Coun 2020;29:748-58. [DOI: 10.1002/jgc4.1202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
22 Stanislaw C, Xue Y, Wilcox WR. Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing. Cancer Biol Med 2016;13:55-67. [PMID: 27144062 DOI: 10.28092/j.issn.2095-3941.2016.0002] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
23 Selkirk CG, Vogel KJ, Newlin AC, Weissman SM, Weiss SM, Wang C, Hulick PJ. Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice. Familial Cancer 2014;13:527-36. [DOI: 10.1007/s10689-014-9741-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
24 Kurian AW, Kingham KE, Ford JM. Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. Curr Opin Obstet Gynecol. 2015;27:23-33. [PMID: 25502425 DOI: 10.1097/gco.0000000000000141] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
25 Byfield SD, Wei H, DuCharme M, Lancaster JM. Economic impact of multigene panel testing for hereditary breast and ovarian cancer. J Comp Eff Res 2021;10:207-17. [PMID: 33491479 DOI: 10.2217/cer-2020-0192] [Reference Citation Analysis]
26 Butz H, Blair J, Patócs A. Molecular genetic testing strategies used in diagnostic flow for hereditary endocrine tumour syndromes. Endocrine 2021;71:641-52. [PMID: 33570725 DOI: 10.1007/s12020-021-02636-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Zhang D, An X, Li Q, Man X, Chu M, Li H, Zhang N, Dai X, Yu H, Li Z. Thioguanine Induces Apoptosis in Triple-Negative Breast Cancer by Regulating PI3K-AKT Pathway. Front Oncol 2020;10:524922. [PMID: 33194583 DOI: 10.3389/fonc.2020.524922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Rohlin A, Rambech E, Kvist A, Törngren T, Eiengård F, Lundstam U, Zagoras T, Gebre-Medhin S, Borg Å, Björk J, Nilbert M, Nordling M. Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing. Fam Cancer 2017;16:195-203. [PMID: 27696107 DOI: 10.1007/s10689-016-9934-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
29 Kwong A, Shin VY, Chen J, Cheuk IWY, Ho CYS, Au CH, Chan KKL, Ngan HYS, Chan TL, Ford JM, Ma ESK. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel. J Mol Diagn 2020;22:544-54. [PMID: 32068069 DOI: 10.1016/j.jmoldx.2020.01.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
30 Gallego CJ, Perez ML, Burt A, Amendola LM, Shirts BH, Pritchard CC, Hisama FM, Bennett RL, Veenstra DL, Jarvik GP. Next Generation Sequencing in the Clinic: a Patterns of Care Study in a Retrospective Cohort of Subjects Referred to a Genetic Medicine Clinic for Suspected Lynch Syndrome. J Genet Couns 2016;25:515-9. [PMID: 26637299 DOI: 10.1007/s10897-015-9902-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
31 McAlarnen L, Stearns K, Uyar D. Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers. Appl Clin Genet 2021;14:1-9. [PMID: 33488111 DOI: 10.2147/TACG.S245021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Ricci MT, Volorio S, Signoroni S, Mariani P, Mariette F, Sardella D, Pensotti V, Vitellaro M. Development, technical validation, and clinical application of a multigene panel for hereditary gastrointestinal cancer and polyposis. Tumori Journal 2019;105:338-52. [DOI: 10.1177/0300891619847085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Bradbury AR, Patrick-Miller LJ, Egleston BL, DiGiovanni L, Brower J, Harris D, Stevens EM, Maxwell KN, Kulkarni A, Chavez T, Brandt A, Long JM, Powers J, Stopfer JE, Nathanson KL, Domchek SM. Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. Genet Med 2016;18:25-33. [PMID: 25834950 DOI: 10.1038/gim.2015.19] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
34 Slavin TP, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer KR, Weitzel JN. Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Front Oncol 2015;5:208. [PMID: 26484312 DOI: 10.3389/fonc.2015.00208] [Cited by in Crossref: 15] [Cited by in F6Publishing: 52] [Article Influence: 2.1] [Reference Citation Analysis]
35 Hooker GW, Clemens KR, Quillin J, Vogel Postula KJ, Summerour P, Nagy R, Buchanan AH. Cancer Genetic Counseling and Testing in an Era of Rapid Change. J Genet Couns 2017;26:1244-53. [PMID: 28434142 DOI: 10.1007/s10897-017-0099-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
36 Medendorp NM, Hillen MA, Murugesu L, Aalfs CM, Stiggelbout AM, Smets EMA. Uncertainty related to multigene panel testing for cancer: a qualitative study on counsellors' and counselees' views. J Community Genet 2019;10:303-12. [PMID: 30430454 DOI: 10.1007/s12687-018-0393-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
37 Yee NS, Lengerich EJ, Schmitz KH, Maranki JL, Gusani NJ, Tchelebi L, Mackley HB, Krok KL, Baker MJ, Boer C, Yee JD. Frontiers in Gastrointestinal Oncology: Advances in Multi-Disciplinary Patient Care. Biomedicines 2018;6:E64. [PMID: 29865163 DOI: 10.3390/biomedicines6020064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
38 Stoll J, Weissman SM, Hook N, Selkirk C, Johnson AK, Newlin A, Vogel Postula KJ. Evaluation of laboratory perspectives on hereditary cancer panels. Fam Cancer 2016;15:689-96. [PMID: 26869169 DOI: 10.1007/s10689-016-9880-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
39 Marcus RK, Geurts JL, Grzybowski JA, Turaga KK, Clark Gamblin T, Strong KA, Johnston FM. Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines. Fam Cancer 2015;14:641-9. [PMID: 26108897 DOI: 10.1007/s10689-015-9817-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
40 Cragun D, Kinney AY, Pal T. Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing. Expert Rev Mol Diagn 2017;17:57-70. [PMID: 27910721 DOI: 10.1080/14737159.2017.1267567] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
41 Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, Hisama FM, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL. Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. J Clin Oncol 2015;33:2084-91. [PMID: 25940718 DOI: 10.1200/JCO.2014.59.3665] [Cited by in Crossref: 88] [Cited by in F6Publishing: 45] [Article Influence: 12.6] [Reference Citation Analysis]
42 Bonadio RC, Crespo JR, Estevez-Diz MDP. Ovarian cancer risk assessment in the era of next-generation sequencing. Ann Transl Med 2020;8:1704. [PMID: 33490216 DOI: 10.21037/atm-20-1582] [Reference Citation Analysis]